Form 4: Cytokinetics Director Sells $143K in Stock

A director at Cytokinetics Inc. sold 2,150 shares of common stock for approximately $143,620 under a pre-arranged trading plan.

Summary

• Robert Arthur Harrington, a Director at Cytokinetics Inc. (CYTK), reported a sale of common stock.
• The transaction involved the disposition of 2,150 shares of common stock.
• The shares were sold at a price of $66.80 per share.
• The total value of the shares sold was approximately $143,620.
• Following this transaction, Mr. Harrington directly beneficially owns 18,542 shares of common stock.
• The transaction was executed on December 1, 2025, pursuant to a Rule 10b5-1 trading plan.

Sentiment

Score: 3

Explanation: The sale of shares by a director, even under a 10b5-1 plan, typically carries a slightly negative sentiment as it can be interpreted as a signal of reduced confidence or a belief that the stock is adequately valued.

Negatives

• A director, Robert Arthur Harrington, sold 2,150 shares of company common stock.
• Insider selling, even when conducted under a Rule 10b5-1 plan, can sometimes be interpreted by the market as a signal of reduced confidence or a belief that the stock may be fully valued.

Risks

• Potential negative market perception due to insider selling, which could impact investor sentiment and stock price.

Future Outlook

N/A. This filing reports a past transaction and does not provide forward-looking statements or guidance.

Industry Context

N/A. This Form 4 filing is specific to an individual director's stock transaction and does not provide broader industry context.

Stakeholder Impact

• Shareholders may interpret the director's sale of shares as a negative signal regarding the company's future prospects or stock valuation, potentially leading to downward pressure on the stock price.

Key Dates

Recommendation

While the sale was conducted under a Rule 10b5-1 plan, indicating it was pre-scheduled and not necessarily based on new material non-public information, insider selling can still be viewed cautiously by investors. It suggests that a key insider believes the current price is a good point to divest some holdings. Investors should hold and monitor future insider activity and company performance.

Keywords

Cytokinetics, CYTK, Form 4, insider trading, stock sale, director transaction, Robert Arthur Harrington, 10b5-1 plan